|
|
Article: Antares Pharma Begins Clinical Trial of Its Needle-Free Drug Delivery System Under the Terms of Previously Announced Option Agreement With Eli Lilly and Company.
- Article from:
- PR Newswire
- Article date:
- April 14, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Antares Pharma, Inc. today announced that IKP (Institut fur Klinische Pharmakologie), a leading contract research organization (CRO) located in Grunstadt, Germany, has received approval and begun the clinical study defined in the extension of Antares Pharma's option agreement with Eli Lilly and Company . This agreement was extended in December 2002 in order to conduct an additional clinical study to support Lilly's evaluation of Antares Pharma's needle-free drug delivery technology.
Roger G. Harrison, Chief Executive Officer and President of Antares Pharma, said, "We are pleased with the progress made since the announcement of the extension of our option ...
Related newspaper, magazine, and journal articles:
|
|
Article: Antares Pharma CEO Dr. Roger G. Harrison Featured ...
PR Newswire;
October 2, 2003 ;
700+ words
... ... Before joining Antares Pharma, Dr. Harrison held various positions at Eli Lilly and Company, including ... Switzerland. About Antares Pharma Antares Pharma recently announced ... license agreement with Eli Lilly and Company for the ...
|
|